Wang Gang, Chen Lei, Jian Wei, Fang Lin
Department of Thyroid and Breast Surgery, Shanghai Tenth People's Hospital, Nanjing Medical University, Shanghai, China.
Department of Thyroid and Breast Surgery, Shanghai Tenth People's Hospital, Nanjing Medical University, Shanghai, China,
Oncol Res Treat. 2021 Feb 5:1-8. doi: 10.1159/000513405.
Breast cancer is one of the most common malignant cancers among women worldwide. MicroRNA-663a (miR-663a) acts as a tumor suppressor gene involved in the development of various cancers.
The aim of this study was to reveal the clinical significance and biological function of miR-663a in breast cancer.
The expression of miR-663a in breast cancer tissues and cells was evaluated by reverse transcription-quantitative polymerase chain reaction. Kaplan-Meier survival and Cox regression analysis were performed to evaluate the prognostic significance of miR-663a in breast cancer. CCK-8 and Transwell assays were used to demonstrate the effect of miR-663a on breast cancer cell function.
We confirmed that the expression of miR-663a was significantly downregulated in breast cancer tissue samples and cell lines. Low miR-663a expression was significantly associated with lymph node metastasis, TNM stage, subtypes, and poor survival in breast cancer patients, indicating that miR-663a is an independent prognostic factor for patients with breast cancer. Cell function experiments revealed that low miR-663a expression promoted cell proliferation, migration, and invasion in breast cancer.
All experimental results demonstrated that miR-663a acts as a tumor suppressor that inhibits the proliferation, migration, and invasion of breast cancer cells, and miR-663a may be a prognostic biomarker and therapeutic target for breast cancer.
乳腺癌是全球女性中最常见的恶性肿瘤之一。微小RNA-663a(miR-663a)作为一种肿瘤抑制基因,参与多种癌症的发生发展。
本研究旨在揭示miR-663a在乳腺癌中的临床意义和生物学功能。
采用逆转录-定量聚合酶链反应评估miR-663a在乳腺癌组织和细胞中的表达。进行Kaplan-Meier生存分析和Cox回归分析,以评估miR-663a在乳腺癌中的预后意义。采用CCK-8和Transwell实验来证明miR-663a对乳腺癌细胞功能的影响。
我们证实miR-663a在乳腺癌组织样本和细胞系中的表达显著下调。miR-663a低表达与乳腺癌患者的淋巴结转移、TNM分期、亚型及不良生存显著相关,表明miR-663a是乳腺癌患者的独立预后因素。细胞功能实验显示,miR-663a低表达促进乳腺癌细胞的增殖、迁移和侵袭。
所有实验结果表明,miR-663a作为一种肿瘤抑制因子,抑制乳腺癌细胞的增殖、迁移和侵袭,miR-663a可能是乳腺癌的预后生物标志物和治疗靶点。